What do systematic reviews say?

Erlotinib vs control

Erlotinib leads to lower progression‐free survival compared with control (high certainty).

• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
  HR 0.31 [0.25, 0.39]
  4 studies · 583 participants
  High